Alejandro Chaoul1, Kathrin Milbury1, Amy Spelman1, Karen Basen-Engquist2, Martica H Hall3, Qi Wei1, Ya-Chen Tina Shih4, Banu Arun5, Vicente Valero5, George H Perkins6, Gildy V Babiera7, Tenzin Wangyal8, Rosalinda Engle1, Carol A Harrison2, Yisheng Li9, Lorenzo Cohen1. 1. Department of Palliative, Rehabilitation, and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2. Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston, Texas. 3. Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania. 4. Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas. 5. Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 6. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 7. Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 8. Ligmincha Institute, Shipman, Virginia. 9. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Abstract
BACKGROUND: The current randomized trial examined the effects of a Tibetan yoga program (TYP) versus a stretching program (STP) and usual care (UC) on sleep and fatigue in women with breast cancer who were undergoing chemotherapy. METHODS:Women with stage (American Joint Committee on Cancer (AJCC) TNM) I to III breast cancer who were undergoing chemotherapy were randomized to TYP (74 women), STP (68 women), or UC (85 women). Participants in the TYP and STP groups participated in 4 sessions during chemotherapy, followed by 3 booster sessions over the subsequent 6 months, and were encouraged to practice at home. Self-report measures of sleep disturbances (Pittsburgh Sleep Quality Index), fatigue (Brief Fatigue Inventory), and actigraphy were collected at baseline; 1 week after treatment; and at 3, 6, and 12 months. RESULTS: There were no group differences noted in total sleep disturbances or fatigue levels over time. However, patients in the TYP group reported fewer daily disturbances 1 week after treatment compared with those in the STP (difference, -0.43; 95% confidence interval [95% CI], -0.82 to -0.04 [P = .03]) and UC (difference, -0.41; 95% CI, -0.77 to -0.05 [P = .02]) groups. Group differences at the other time points were maintained for TYP versus STP. Actigraphy data revealed greater minutes awake after sleep onset for patients in the STP group 1 week after treatment versus those in the TYP (difference, 15.36; 95% CI, 7.25-23.48 [P = .0003]) and UC (difference, 14.48; 95% CI, 7.09-21.87 [P = .0002]) groups. Patients in the TYP group who practiced at least 2 times a week during follow-up reported better Pittsburgh Sleep Quality Index and actigraphy outcomes at 3 months and 6 months after treatment compared with those who did not and better outcomes compared with those in the UC group. CONCLUSIONS: Participating in TYP during chemotherapy resulted in modest short-term benefits in sleep quality, with long-term benefits emerging over time for those who practiced TYP at least 2 times a week. Cancer 2018;124:36-45.
RCT Entities:
BACKGROUND: The current randomized trial examined the effects of a Tibetan yoga program (TYP) versus a stretching program (STP) and usual care (UC) on sleep and fatigue in women with breast cancer who were undergoing chemotherapy. METHODS:Women with stage (American Joint Committee on Cancer (AJCC) TNM) I to III breast cancer who were undergoing chemotherapy were randomized to TYP (74 women), STP (68 women), or UC (85 women). Participants in the TYP and STP groups participated in 4 sessions during chemotherapy, followed by 3 booster sessions over the subsequent 6 months, and were encouraged to practice at home. Self-report measures of sleep disturbances (Pittsburgh Sleep Quality Index), fatigue (Brief Fatigue Inventory), and actigraphy were collected at baseline; 1 week after treatment; and at 3, 6, and 12 months. RESULTS: There were no group differences noted in total sleep disturbances or fatigue levels over time. However, patients in the TYP group reported fewer daily disturbances 1 week after treatment compared with those in the STP (difference, -0.43; 95% confidence interval [95% CI], -0.82 to -0.04 [P = .03]) and UC (difference, -0.41; 95% CI, -0.77 to -0.05 [P = .02]) groups. Group differences at the other time points were maintained for TYP versus STP. Actigraphy data revealed greater minutes awake after sleep onset for patients in the STP group 1 week after treatment versus those in the TYP (difference, 15.36; 95% CI, 7.25-23.48 [P = .0003]) and UC (difference, 14.48; 95% CI, 7.09-21.87 [P = .0002]) groups. Patients in the TYP group who practiced at least 2 times a week during follow-up reported better Pittsburgh Sleep Quality Index and actigraphy outcomes at 3 months and 6 months after treatment compared with those who did not and better outcomes compared with those in the UC group. CONCLUSIONS: Participating in TYP during chemotherapy resulted in modest short-term benefits in sleep quality, with long-term benefits emerging over time for those who practiced TYP at least 2 times a week. Cancer 2018;124:36-45.
Authors: Julienne E Bower; Deborah Garet; Beth Sternlieb; Patricia A Ganz; Michael R Irwin; Richard Olmstead; Gail Greendale Journal: Cancer Date: 2011-12-16 Impact factor: 6.860
Authors: Alyson B Moadel; Chirag Shah; Judith Wylie-Rosett; Melanie S Harris; Sapana R Patel; Charles B Hall; Joseph A Sparano Journal: J Clin Oncol Date: 2007-09-04 Impact factor: 44.544
Authors: R M Raghavendra; R Nagarathna; H R Nagendra; K S Gopinath; B S Srinath; B D Ravi; S Patil; B S Ramesh; R Nalini Journal: Eur J Cancer Care (Engl) Date: 2007-11 Impact factor: 2.520
Authors: M Raghavendra Rao; Nagarathna Raghuram; H R Nagendra; K S Gopinath; B S Srinath; Ravi B Diwakar; Shekar Patil; S Ramesh Bilimagga; Nalini Rao; S Varambally Journal: Complement Ther Med Date: 2008-10-14 Impact factor: 2.446
Authors: Susan L Beck; Ann M Berger; Andrea M Barsevick; Bob Wong; Katie A Stewart; William N Dudley Journal: Support Care Cancer Date: 2009-06-13 Impact factor: 3.603
Authors: James W Carson; Kimberly M Carson; Laura S Porter; Francis J Keefe; Heather Shaw; Julie M Miller Journal: J Pain Symptom Manage Date: 2007-03 Impact factor: 3.612
Authors: Suzanne C Danhauer; Elizabeth L Addington; Lorenzo Cohen; Stephanie J Sohl; Marieke Van Puymbroeck; Natalia K Albinati; S Nicole Culos-Reed Journal: Cancer Date: 2019-04-01 Impact factor: 6.860
Authors: Nick Gebruers; Melissa Camberlin; Fleur Theunissen; Wiebren Tjalma; Hanne Verbelen; Timia Van Soom; Eric van Breda Journal: Support Care Cancer Date: 2018-10-09 Impact factor: 3.603
Authors: Chelsea G Ratcliff; Stephanie G Zepeda; Martica H Hall; Emily A Tullos; Shaelyn Fowler; Alejandro Chaoul; Amy Spelman; Banu Arun; Lorenzo Cohen Journal: Support Care Cancer Date: 2020-09-22 Impact factor: 3.603